# US 2025/0368751 A1 · USE of Antibody Mutation FOR Therapeutic Antibody Drug

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0368751 A1
- Document ID: US20250368751A1
- Status: Published application
- Kind: A1
- Application number: 19/136,891
- Filed: 2022-12-23
- Published: 2025-12-04
- Earliest claimed: 2022-10-13
- Assignees: Shenzhen Baishitong Technology Development Company Limited
- Applicants: Shenzhen Baishitong Technology Development Company Limited
- Inventors: Jing LOU; Jianhe CHEN; Dongmei SU; Zheng JIN; Yunying LV; Ruolan ZHANG; Ruochen PEI; Yanmei OU; Xiao QU; Xie XIE; Jing ZHANG; Lin ZENG
- Web page: https://patentgrep.com/patent/US20250368751A1

## CPC

- C07K 16/32: against translation products of oncogenes
- A61P 35/00: Antineoplastic agents
- C07K 14/54: Interleukins [IL]
- C07K 14/5428: {IL-10}
- C07K 14/5434: {IL-12}
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 16/244: {Interleukins [IL]}
- C07K 16/246: {IL-2}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides a bifunctional molecule formed by connecting an Fc-mutated antibody to a cytokine, and use of the bifunctional molecule in the preparation of a therapeutic antibody drug. These Fc-mutated monoclonal antibodies or monoclonal antibody/antigen complexes or Fc fusion proteins can significantly reduce in vivo toxic side effects while maintaining their pre-mutation in vivo and in vitro biological activity.

## Claims

### Claim 1

A bifunctional molecule, comprising an Fc-mutated antibody and cytokine, wherein the Fc-mutated antibody and the cytokine are connected.

### Claim 2 (depends on 1)

The bifunctional molecule according to claim 1, wherein an Fc mutation in the Fc-mutated antibody is selected from:
H310A/H435Q, 1253A, S254A, R255A, K288A, L309A, H310A, S415A, H433A, H435A, H435R, Y436A, H310Q/H433N, M252Y/T256Q, and M252F/T256D.

### Claim 3 (depends on 1)

The bifunctional molecule according to claim 1, wherein the antibody is selected from:
IgG1, IgG4, HER2, HER3, EGFR, PDL1, CD19, CD20, CD22, CD24, CD33, CD40, CD40L, CD73, CD276, VEGFR, TIGIT, TIM3, LAG3,CXCR3, CXCR5, CCR3, CCR4, CCR9, and PD1.

### Claim 4 (depends on 1)

The bifunctional molecule according to claim 1, wherein the cytokine is selected from:
IL2 and mutants thereof, IL7, IL12 and mutants thereof, IL15, IL18, IL21, IL2-CD25, Neo 2/15, IFNα, IFNα2b and mutants thereof, IFNγ, TNFα, GM-CSF, FLt3, and CCL21.

### Claim 5 (depends on 1)

A method for amplifying the bifunctional molecule according to claim 1, comprising:
connecting the cytokine to the Fc-mutated antibody to form a fusion protein;
constructing the fusion protein into an expression vector;
transfecting the expression vector into cells, and
performing purification.

### Claim 6 (depends on 1)

A therapeutic antibody drug, comprising the bifunctional molecule according to claim 1.

### Claim 7 (depends on 1)

A use of the bifunctional molecule according to claim 1 in the preparation of a drug.

### Claim 8 (depends on 7)

The use according to claim 7, wherein the drug is a therapeutic antibody drug.
